Literature DB >> 7109844

The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats.

F J Ehlert, W R Roeske, E Itoga, H I Yamamura.   

Abstract

The binding properties of the calcium channel antagonist, [3H]nitrendipine, were investigated in homogenates of the rat cerebral cortex, heart and ileum. The specific component of [3H]nitrendipine binding was consistent with mass-action behavior and was characterized by a high affinity dissociation constant in the range of 0.1-0.3 nM. A variety of other calcium channel antagonists inhibited the binding of [3H]nitrendipine with Ki's that agree generally with the ability of these drugs to block contractions of cardiac and smooth muscle. The inhibition of [3H]nitrendipine binding by other dihydropyridines was consistent with competitive antagonism whereas the inhibition caused by verapamil and D600 resembled negative heterotropic cooperativity. Consistent with this latter postulate was the observation that the kinetics of [3H]nitrendipine binding are altered by verapamil, with both the association rate and the dissociation rate being increased. La+3 and several divalent cations caused an inhibition of [3H]nitrendipine with the rank order of potency being Cd+2 greater than La+3 greater than Ni+2 greater than Co+2 = Mn+2 greater than Mg+2 = Ba+2 greater than Ca+2.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7109844     DOI: 10.1016/0024-3205(82)90293-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  29 in total

1.  L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations.

Authors:  E C Keung; L Toll; M Ellis; R A Jensen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  A calmodulin-like ca receptor in the ca channel.

Authors:  J D Johnson
Journal:  Biophys J       Date:  1984-01       Impact factor: 4.033

3.  Photoaffinity labelling of the cardiac calcium channel. (-)-[3H]azidopine labels a 165 kDa polypeptide, and evidence against a [3H]-1,4-dihydropyridine-isothiocyanate being a calcium-channel-specific affinity ligand.

Authors:  D R Ferry; A Goll; H Glossmann
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

4.  Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.

Authors:  N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

5.  A unitary mechanism of calcium antagonist drug action.

Authors:  K M Murphy; R J Gould; B L Largent; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

6.  Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites.

Authors:  M R Bristow; R Ginsburg; J A Laser; B J McAuley; W Minobe
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

7.  Direct inhibitory effects of some 'calcium-antagonists' and trifluoperazine on the contractile proteins in smooth muscle.

Authors:  M Spedding
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

8.  Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats.

Authors:  S Yamada; Y Matsuoka; R Kimura
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.

Authors:  B Larsson; E D Högestätt; A Mattiasson; K E Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats.

Authors:  S Uchida; S Yamada; T Ohkura; M Heshikiri; A Yoshimi; H Shirahase; R Kimura
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.